Back to Journals » Research and Reviews in Parkinsonism » Volume 2

Tolerability of atypical neuroleptics and acetylcholinesterase inhibitors when treating neuropsychiatric symptoms in Parkinson's disease

Authors Tolleson C, Fang J, Lu P, Wu H, Davis T

Received 28 August 2012

Accepted for publication 28 August 2012

Published 26 September 2012 Volume 2012:2 Pages 37—43

DOI https://doi.org/10.2147/JPRLS.S37450


Christopher Tolleson,1 John Fang,1 Pengcheng Lu,2 Huiyun Wu,2 Thomas Davis1

1Movement Disorders, Department of Neurology, 2Department of Biostatistics, Vanderbilt University, Nashville, TN, USA

Background: Treating neuropsychiatric problems in Parkinson's disease (PD) remains challenging. Only rivastigmine has US Food and Drug Administration approval for the treatment of PD dementia. Some studies have shown that atypical neuroleptics adequately improve hallucinations while others suggest that side effects and increased mortality negate benefit. We utilized a chart review to assess the tolerability and efficacy of commonly used agents for neuropsychiatric symptoms in PD.
Methods: We reviewed patients with a PD diagnosis in our clinic database who were being treated with antidementia agents (donepezil, galantamine, rivastigmine, memantine) or atypical neuroleptics (quetiapine, olanzapine, clozapine) by two PD specialists over 13 years. We determined tolerability by therapy retention in comparison with the accepted gold standard, ie, rivastigmine for dementia and clozapine for hallucinations. Clinician documentation of patient/caregiver or personally perceived clinical improvement was recorded to define therapeutic response. Secondary outcome measures were death, treatment-limiting side effects, and weight change.
Results: A total of 171 PD patients met criteria for study inclusion. All medications were similarly retained in comparison with the standard, with the exception of donepezil which was significantly better (P < 0.02) than rivastigmine. Using the documentation metric, no medication was statistically superior to its standard. Olanzapine approached significance because it was inferior to the clozapine standard (P < 0.08). Secondary outcome measures were similar among medications.
Conclusion: We conclude that, as a group, acetylcholinesterase inhibitors, atypical neuroleptics, and memantine are well tolerated in treating either cognitive difficulties or hallucinations in PD. They appear to offer variable levels of clinical benefit, as well per documented therapeutic responses. Side effects, death, and weight change were not significantly different among medications.

Keywords: Parkinson's disease, atypical neuroleptics, acetylcholinesterase inhibitors, dementia, hallucinations

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]